Funding secured for the CapFuran® toxicity study

We are pleased to announce that our CSO, Dr Jenny Rohn, recently secured funding as the principal investigator on a competitive grant from UCL Innovation & Enterprise, in the Discovery-to-use scheme.

Image of the drug capsules

Photo: K. Lau

The scheme is funded by the UK Engineering and Physical Sciences Research Council. Prof Mohan Edirisinghe, one of AtoCap’s founders, is the co-investigator on the project.

Entitled ‘Gateway to commercialization: a rodent toxicity package for the antimicrobial therapy CapFuran®’, this academic funding will allow AtoCap to couduct a routine toxicology study of CapFuran®, which is the last regulatory hurdle before clinical trials can commence.

Good manufacturing practice (GMP)-compliant batches of AtoCap’s first product CapFuran® are currently being produced for parallel toxicity and stability testing, in preparation for a combined Phase I/II clinical trial in patients with complicated urinary tract infections.


Back to news index